锝亞甲基二膦酸鹽注射液
時間:2015-02-02 06:04:57
云克系列
YUNKE SERIES
二十世紀九十年代公司成功研制的“云克”藥物,是我國自六十年代起至今兩個國產核素藥物之一(其他核素藥物均為進口或仿制藥物)。
In 1990s ,the company developed the drug ‘YUNKE’ succeessfully. It is one of two nuclide drugs developed in our country since 1960s(the else all are imported or modeled medicaments).
“云克”是我國首個用于RA臨床治療的核素藥物,并榮獲國家發明專利(ZL94113006.1)以及“國家重點新產品”證書。
YUNKE is the first nuclide medicament to cure the rheumatoid arthritis. It awarded the government invention patent (ZL 94113006.1) and the certificate of ‘ State Important New Product’.
于2001年獲得國家藥品監督管理局的認可,可以作為普通藥品在臨床進行流通使用。
Certificated by SFDA in 2001, YUNKE could be used as common chemistry medicine in clinic.
通過與全國逾百家科研機構進行科研協作,對“云克”藥物的治療機理及臨床療效等進行了多方實驗及臨床驗證:“云克”能通過獨特的免疫調節機制,降低IL-1、IL-6、TNF-α、MMP3等多種標志性細胞因子水平,抑制破骨細胞活性,同時促進成骨細胞分裂增殖,從而修復骨侵蝕,恢復關節功能。
Through the scientific research cooperation with over 100 national institutions, it has been validated that YUNKE can reduce significant manifold cell level significant, include IL-1, IL-6, TNF-α, MMP3 and soon, by the unique mechanism to adjust the immunity function. Furthermore, it can recover the bone lacuna and joint function via prohibit activity of osteoclast and while facilitating the division osteoblast.
“云克”藥物毒副作用少而輕微,比常用的Anti-RA藥物毒性低。通過對部分患者長達三年的追蹤發現,“云克”無一般Anti-RA藥物引起的胃腸、肝腎方面的不良反應,也無致癌傾向。10萬人次以上臨床應用證明“云克”治療類風濕性關節炎是非常安全的。
The side-effect of YUNKE was few and gentle than the common used Anti-RA drugs. Through follow up of part patients for 3 years, it was found that YUNKE has not side function to digestive system liver and kidney as common used Anti-RA drugs. The clinic uses of 100,000 patients proved YUNKE is very safe for RA treatment.
十年來的臨床應用表明“云克”治療類風濕性關節炎總有效率達85%以上,患者生活質量大幅度改善,部分癱瘓病人經過“云克”治療后能在一定程度上恢復生活自理能力。
Over 10 years clinic uses, it was proved that the total cure rate was over 85%, the patients life quality improved greatly, part of labourless patients can do something by themselves in dayly life after treatment with YUNKE.
現普遍用于治療類風濕性關節炎、強直性脊柱炎、甲亢突眼、腫瘤骨轉移等免疫性疾病和骨性疾病。
YUNKE used broad to cure the immunity and bone disease, such as RA, AS, GO, ANFH and metastasis bone.